-+ 0.00%
-+ 0.00%
-+ 0.00%

UTokyo IPC Portfolio Company Beren Therapeutics Wins FDA Approval for LEMBAZ to Treat Niemann-Pick Disease Type C

PUBT·11/19/2026 00:42:39
Listen to the news
UTokyo IPC Portfolio Company Beren Therapeutics Wins FDA Approval for LEMBAZ to Treat Niemann-Pick Disease Type C
  • Beren Therapeutics received U.S. FDA approval for LEMBAZ (adrabetadex), a therapy for Niemann-Pick disease type C.
  • The UTokyo IPC portfolio company announced the approval on November 17, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. UTokyo Innovation Platform Co Ltd published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.